The Medical Letter on Drugs and Therapeutics
Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved inotuzumab ozogamicin (Besponsa – Pfizer), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It is the first CD22-directed antibody-drug conjugate to be approved in the US.

RELAPSED OR REFRACTORY ALL — Induction chemotherapy induces a complete remission in 60-90% of adults with newly-diagnosed ALL, but most of these patients will subsequently relapse. The goal for patients who do not respond to induction therapy and those who respond initially and then relapse is to achieve a complete remission, or close to it, in order to proceed to an allogeneic hematopoietic cell transplant (HCT), which can be curative.1

MECHANISM OF ACTION — The antibody-drug conjugate binds to CD22, which ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
Article code: 1547f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian